The DOI matches its Crossref record; 84 of the 84 references it cites were found in a registry or an index.
p53 Mutations in Human Cancers
Abstract
Mutations in the evolutionarily conserved codons of the p53 tumor suppressor gene are common in diverse types of human cancer. The p53 mutational spectrum differs among cancers of the colon, lung, esophagus, breast, liver, brain, reticuloendothelial tissues, and hemopoietic tissues. Analysis of these mutations can provide clues to the etiology of these diverse tumors and to the function of specific regions of p53. Transitions predominate in colon, brain, and lymphoid malignancies, whereas G:C to T:A transversions are the most frequent substitutions observed in cancers of the lung and liver. Mutations at A:T base pairs are seen more frequently in esophageal carcinomas than in other solid tumors. Most transitions in colorectal carcinomas, brain tumors, leukemias, and lymphomas are at CpG dinucleotide mutational hot spots. G to T transversions in lung, breast, and esophageal carcinomas are dispersed among numerous codons. In liver tumors in persons from geographic areas in which both aflatoxin B 1 and hepatitis B virus are cancer risk factors, most mutations are at one nucleotide pair of codon 249. These differences may reflect the etiological contributions of both exogenous and endogenous factors to human carcinogenesis.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Sequencing of commonly mutated exons 5 through 9 (39) of the p53 gene by using DNA isolated from the frozen tumors did not reveal any mutations.”
From Ink4a / Arf tumor suppressor does not modulate the degenerative conditions or tumor spectrum of the telomerase-deficient mouse (2007) · cites this paper as [39]
In the citing paper
“loss of TP53 provides a selective advantage for neoplastic growth18.”
From Role of TP53 mutations in the origin and evolution of therapy-related acute myeloid leukaemia (2015) · cites this paper as [18]
Citations
Cites
Barbacid, M. (1987) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.56.070187.004023 · Cited by 3,885
Germ Line p53 Mutations in a Familial Syndrome of Breast Cancer, Sarcomas, and Other Neoplasms
Malkin, D., Li, F. P., Strong, L. C., Fraumeni, J. F., Nelson, C. E., Kim, D. H., Kassel, J., Gryka, M. A., Bischoff, F. Z., Tainsky, M. A., et al. (1990) · Science · doi:10.1126/science.1978757 · Cited by 3,765
Mutations in the p53 gene occur in diverse human tumour types
Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hosteller, R., Cleary, K. R., Signer, S. H., Davidson, N. E., Baylin, S., Devilee, P., et al. (1989) · Nature · doi:10.1038/342705a0 · Cited by 2,730
Self-citationAssociation of Human Papillomavirus Types 16 and 18 E6 Proteins with p53
Werness, B. A., Levine, A. J., & Howley, P. M. (1990) · Science · doi:10.1126/science.2157286 · Cited by 2,562
T antigen is bound to a host protein in SY40-transformed cells
Lane, D. P., & Crawford, L. V. (1979) · Nature · doi:10.1038/278261a0 · Cited by 2,456
Insertion of specific bases during DNA synthesis past the oxidation-damaged base 8-oxodG
Shibutani, S., Takeshita, M., & Grollman, A. P. (1991) · Nature · doi:10.1038/349431a0 · Cited by 2,224
Chromosome 17 Deletions and p53 Gene Mutations in Colorectal Carcinomas
Baker, S. J., Fearon, E. R., Nigro, J. M., Hamilton, S. R., Preisinger, A. C., Jessup, J. M., vanTuinen, P., Ledbetter, D. H., Barker, D. F., Nakamura, Y., et al. (1989) · Science · doi:10.1126/science.2649981 · Cited by 2,097
Self-citationThe p53 proto-oncogene can act as a suppressor of transformation
Finlay, C. A., Hinds, P. W., & Levine, A. J. (1989) · Cell · doi:10.1016/0092-8674(89)90045-7 · Cited by 1,987
Linzer, D. I. H., & Levine, A. J. (1979) · Cell · doi:10.1016/0092-8674(79)90293-9 · Cited by 1,814
Suppression of Human Colorectal Carcinoma Cell Growth by Wild-Type p53
Baker, S. J., Markowitz, S. D., Fearon, E. R., Willson, J. K. V., & Vogelstein, B. (1990) · Science · doi:10.1126/science.2144057 · Cited by 1,742
Self-citation
Flagged first, then by citations
Research works printed but not linked: 6
- Bennett, W., Oncogene 6: 1779 (1991).
- CASSON, A. C., JOURNAL OF CELLULAR BIOCHEMISTRY 47 15F: 21 (1991).
- Gaidano, G., Proceedings of the National Academy of Sciences of the United States of America 88: 5413 (1991).
- Lehman, T., Cancer Research 51: 4090 (1991).
- Mashiyama, S., Oncogene 6: 1313 (1991).
- 10.1126/science.2144363 · DOI
Cited by
Sorted by citations
Items 101–158 of 158
The role of ubiquitin modification in the regulation of p53
Hock, A. K., & Vousden, K. H. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2013.05.022 · Cited by 168
Ambs, S., Bennett, W. P., Merriam, W. G., Ogunfusika, M. O., Oser, S. M., Harrington, A. M., Shields, P. G., Felley-Bosco, E., Hussain, S. P., & Harris, C. C. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.1.86 · Cited by 166
Self-citationANDERSON, N. B. (1998) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.1998.tb09595.x · Cited by 165
Ser18 and 23 phosphorylation is required for p53‐dependent apoptosis and tumor suppression
Chao, C., Herr, D., Chun, J., & Xu, Y. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601167 · Cited by 158
Sarfstein, R., Friedman, Y., Attias-Geva, Z., Fishman, A., Bruchim, I., & Werner, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0061537 · Cited by 150
The Pathobiochemistry of Nitrogen Dioxide
Kirsch, M., Korth, H.-G., Sustmann, R., & Groot, H. D. (2002) · Biological Chemistry · doi:10.1515/bc.2002.043 · Cited by 150
Hsp90-binding immunophilins link p53 to dynein during p53 transport to the nucleus
Galigniana, M. D., Harrell, J. M., O'Hagen, H. M., Ljungman, M., & Pratt, W. B. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m402223200 · Cited by 150
Another fork in the road—life or death decisions by the tumour suppressor p53
Carvajal, L. A., & Manfredi, J. J. (2013) · The EMBO Reports · doi:10.1038/embor.2013.25 · Cited by 149
Cell Type- and Promoter-specific Roles of Ser18 Phosphorylation in Regulating p53 Responses
Chao, C., Hergenhahn, M., Kaeser, M. D., Wu, Z., Saito, S., Iggo, R., Hollstein, M., Appella, E., & Xu, Y. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m306938200 · Cited by 141
Self-citationp53 Mutations in sporadic adrenocortical tumors
Ohgaki, H., Kleihues, P., & Heitz, P. U. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540310 · Cited by 139
Mutational spectrum of p53 mutations in primary breast and ovarian tumors
Feki, A., & Irminger-Finger, I. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.07.002 · Cited by 139
Acquisition of p53 mutations in response to the non-genotoxic p53 activator Nutlin-3
Aziz, M. H., Shen, H., & Maki, C. G. (2011) · Oncogene · doi:10.1038/onc.2011.185 · Cited by 131
mCSM-NA: predicting the effects of mutations on protein-nucleic acids interactions
Pires, D. E. V., & Ascher, D. B. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkx236 · Cited by 127
Understanding mutagenesis through delineation of mutational signatures in human cancer
Petljak, M., & Alexandrov, L. B. (2016) · Carcinogenesis · doi:10.1093/carcin/bgw055 · Cited by 110
Discovery of a Small Molecule MDM2 Inhibitor (AMG 232) for Treating Cancer
Rew, Y., & Sun, D. (2014) · Journal of Medicinal Chemistry · doi:10.1021/jm500627s · Cited by 125
Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3
LeBron, C., Chen, L., Gilkes, D. M., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601032 · Cited by 122
Increased Sensitivity to UV Radiation in Mice with a p53 Point Mutation at Ser389
Bruins, W., Zwart, E., Attardi, L. D., Iwakuma, T., Hoogervorst, E. M., Beems, R. B., Miranda, B., van Oostrom, C. T. M., van den Berg, J., van den Aardweg, G. J., et al. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.20.8884-8894.2004 · Cited by 121
Proteolytic Cleavage of the mdm2 Oncoprotein during Apoptosis
Chen, L., Marechal, V., Moreau, J., Levine, A. J., & Chen, J. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.36.22966 · Cited by 121
Wild-Type Human p53 Transactivates the Human Proliferating Cell Nuclear Antigen Promoter
Shivakumar, C. V., Brown, D. R., Deb, S., & Deb, S. P. (1995) · Molecular and Cellular Biology · doi:10.1128/mcb.15.12.6785 · Cited by 120
Portrait of a cancer: mutational signature analyses for cancer diagnostics
Van Hoeck, A., Tjoonk, N. H., van Boxtel, R., & Cuppen, E. (2019) · BMC Cancer · doi:10.1186/s12885-019-5677-2 · Cited by 107
Mutations of the p53 and PTCH gene in basal cell carcinomas: UV mutation signature and strand bias
Kim, M. (2002) · Journal of Dermatological Science · doi:10.1016/s0923-1811(01)00170-0 · Cited by 116
Regulation of DNA damage recognition and nucleotide excision repair: another role for p53
Ford, J. M. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2005.04.005 · Cited by 117
The G2 Checkpoint Is Maintained by Redundant Pathways
Passalaris, T. M., Benanti, J. A., Gewin, L., Kiyono, T., & Galloway, D. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5872 · Cited by 116
Spurgers, K. B., Gold, D. L., Coombes, K. R., Bohnenstiehl, N. L., Mullins, B., Meyn, R. E., Logothetis, C. J., & McDonnell, T. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513901200 · Cited by 114
Gannon, H. S., Woda, B. A., & Jones, S. N. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.04.011 · Cited by 105
Dhar, S. K., Tangpong, J., Chaiswing, L., Oberley, T. D., & St. Clair, D. K. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1233 · Cited by 106
Mutation of Mouse p53 Ser23 and the Response to DNA Damage
Wu, Z., Earle, J., Saito, S., Anderson, C. W., Appella, E., & Xu, Y. (2002) · Molecular and Cellular Biology · doi:10.1128/mcb.22.8.2441-2449.2002 · Cited by 103
Di Lello, P., Pastor, R., Murray, J. M., Blake, R. A., Cohen, F., Crawford, T. D., Drobnick, J., Drummond, J., Kategaya, L., Kleinheinz, T., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01293 · Cited by 90
Cytotoxic and Antitumor Activity of Sulforaphane: The Role of Reactive Oxygen Species
Sestili, P., & Fimognari, C. (2015) · BioMed Research International · doi:10.1155/2015/402386 · Cited by 90
Kojima, K., Burks, J. K., Arts, J., & Andreeff, M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0337 · Cited by 78
A p53-independent role for the MDM2 antagonist Nutlin-3 in DNA damage response initiation
Valentine, J. M., Kumar, S., & Moumen, A. (2011) · BMC Cancer · doi:10.1186/1471-2407-11-79 · Cited by 77
High expression of RAB27A and TP53 in pancreatic cancer predicts poor survival
Wang, Q., Ni, Q., Wang, X., Zhu, H., Wang, Z., & Huang, J. (2015) · Medical Oncology · doi:10.1007/s12032-014-0372-2 · Cited by 70
Extensive Post-translational Modification of Active and Inactivated Forms of Endogenous p53
DeHart, C. J., Chahal, J. S., Flint, S. J., & Perlman, D. H. (2014) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m113.030254 · Cited by 70
p53 pathway is involved in cell competition during mouse embryogenesis
Zhang, G., Xie, Y., Zhou, Y., Xiang, C., Chen, L., Zhang, C., Hou, X., Chen, J., Zong, H., & Liu, G. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1617414114 · Cited by 69
Zhang, F., Tagen, M., Throm, S., Mallari, J., Miller, L., Guy, R. K., Dyer, M. A., Williams, R. T., Roussel, M. F., Nemeth, K., et al. (2011) · Drug Metabolism and Disposition · doi:10.1124/dmd.110.035915 · Cited by 67
p53 protein accumulation and gene mutations in human glioma cell lines
Anker, L., Ohgaki, H., Ludeke, B. I., Herrmann, H., Kleihues, P., & Westphal, M. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910550618 · Cited by 66
Azmi, A. S., Aboukameel, A., Banerjee, S., Wang, Z., Mohammad, M., Wu, J., Wang, S., Yang, D., Philip, P. A., Sarkar, F. H., et al. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.01.015 · Cited by 67
p53‐mediated adaptation to serine starvation is retained by a common tumour‐derived mutant
Humpton, T. J., Hock, A. K., Maddocks, O. D. K., & Vousden, K. H. (2018) · Cancer & Metabolism · doi:10.1186/s40170-018-0191-6 · Cited by 58
Higgins, B., Glenn, K., Walz, A., Tovar, C., Filipovic, Z., Hussain, S., Lee, E., Kolinsky, K., Tannu, S., Adames, V., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0460 · Cited by 63
Chiappori, A. A., Williams, C. C., Gray, J. E., Tanvetyanon, T., Haura, E. B., Creelan, B. C., Thapa, R., Chen, D.-T., Simon, G. R., Bepler, G., et al. (2019) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-018-2287-9 · Cited by 64
McAndrew, J., Patel, R. P., Jo, H., Cornwell, T., Lincoln, T., Moellering, D., White, C. R., Matalon, S., & Darley-Usmar, V. (1997) · Seminars in Perinatology · doi:10.1016/s0146-0005(97)80002-x · Cited by 56
Khoo, C. M., Carrasco, D. R., Bosenberg, M. W., Paik, J.-H., & DePinho, R. A. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700093104 · Cited by 52
Halazonetis, T. D. (2004) · DNA repair · doi:10.1016/j.dnarep.2004.03.036 · Cited by 53
Azmi, A. S., Banerjee, S., Ali, S., Wang, Z., Bao, B., Beck, F. W. J., Maitah, M., Choi, M., Shields, T. F., Philip, P. A., et al. (2011) · Oncotarget · doi:10.18632/oncotarget.269 · Cited by 48
P53 Protein Accumulation in Lung Carcinomas of Patients Exposed to Asbestos and Tobacco Smoke
Nuorva, K., Mäkitaro, R., Huhti, E., Kamel, D., Vähäkangas, K., Bloigu, R., Soini, Y., & Pääkkö, P. (1994) · American journal of respiratory and critical care medicine · doi:10.1164/ajrccm.150.2.8049841 · Cited by 43
Krex, D., Mohr, B., Appelt, H., Schackert, H. K., & Schackert, G. (2003) · Neurosurgery · doi:10.1227/01.neu.0000093426.29236.86 · Cited by 42
Small molecules that bind the Mdm2 RING stabilize and activate p53
Roxburgh, P., Hock, A. K., Dickens, M. P., Mezna, M., Fischer, P. M., & Vousden, K. H. (2012) · Carcinogenesis · doi:10.1093/carcin/bgs092 · Cited by 43
Zhu, N., Gu, L., Li, F., & Zhou, M. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0179 · Cited by 42
An LTR retrotransposon‐derived lncRNA interacts with RNF169 to promote homologous recombination
Deng, B., Xu, W., Wang, Z., Liu, C., Lin, P., Li, B., Huang, Q., Yang, J., Zhou, H., & Qu, L. (2019) · The EMBO Reports · doi:10.15252/embr.201847650 · Cited by 40
The emerging functions of the p53-miRNA network in stem cell biology
Lin, C.-P., Choi, Y. J., Hicks, G. G., & He, L. (2012) · Cell Cycle · doi:10.4161/cc.20207 · Cited by 38
Therapeutic targeting of TP53-mutated acute myeloid leukemia by inhibiting HIF-1α with echinomycin
Wang, Y., Liu, Y., Bailey, C., Zhang, H., He, M., Sun, D., Zhang, P., Parkin, B., Baer, M. R., Zheng, P., et al. (2020) · Oncogene · doi:10.1038/s41388-020-1201-z · Cited by 38
USP7 protects genomic stability by regulating Bub3.
Giovinazzi, S., Sirleto, P., Aksenova, V., Morozov, V. M., Zori, R., Reinhold, W. C., & Ishov, A. M. (2014) · Oncotarget · doi:10.18632/oncotarget.1989 · Cited by 34
Methylation alterations at imprinted genes detected among long‐term shiftworkers
Jacobs, D. I., Hansen, J., Fu, A., Stevens, R. G., Tjonneland, A., Vogel, U. B., Zheng, T., & Zhu, Y. (2013) · Environmental and Molecular Mutagenesis · doi:10.1002/em.21752 · Cited by 34
“Finally, TP73 is an important component of the p53 family of cell-cycle regulatory proteins, which is expected to be altered in the majority of cancers [Hollstein et al., 1991; Sigal and Rotter, 2000].”
BackgroundBetween Scylla and Charybdis: p53 links tumor suppression and aging
Campisi, J. (2002) · Mechanisms of Ageing and Development · doi:10.1016/s0047-6374(02)00006-4 · Cited by 33
Shimada, Y., Watanabe, G., Yamasaki, S., Maeda, M., Kawabe, A., Kaganoi, J.-I., Itami, A., Fukumoto, M., Kanda, Y., & Imamura, M. (2000) · European Journal of Cancer · doi:10.1016/s0959-8049(00)00049-6 · Cited by 32
Günther, T., Schneider-Stock, R., Ryš, J., Niezabitowski, A., & Roessner, A. (1997) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/bf01240122 · Cited by 28
Lenos, K., de Lange, J., Teunisse, A. F., Lodder, K., Verlaan-de Vries, M., Wiercinska, E., van der Burg, M. J., Szuhai, K., & Jochemsen, A. G. (2011) · Molecular Cancer · doi:10.1186/1476-4598-10-111 · Cited by 16
Efficacy and safety of immune checkpoint blockade in patients with Li-Fraumeni syndrome
Bottosso, M., Verret, B., Caron, O., Hamzaoui, N., Pasmant, E., Danlos, F.-X., Boudou-Rouquette, P., Srikaran, A., Blons, H., Guarneri, V., et al. (2024) · JCO Precision Oncology · doi:10.1200/po.24.00139 · Cited by 6
Metadata
- Authors
- Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C.
- Affiliations
- National Institutes of Health (US)
- Johns Hopkins University (US)
- Venue
- Science
- Published
- 1991-07-05
- Volume
- 253
- Issue
- 5015
- Pages
- 49-53
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2042316019
- Cited by
- 8,018
- References
- 84
- Citations by year
- 2026: 24 · 2025: 53 · 2024: 69 · 2023: 98 · 2022: 114 · 2021: 124 · 2020: 120 · 2019: 121 · 2018: 123 · 2017: 144 · 2016: 152 · 2015: 172 · 2014: 222 · 2013: 208 · 2012: 214
- FWCI
- 182.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Cancer Institute (CA 09071, CA43460, T32CA009071)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pathology and Forensic Medicine › Genetic factors in colorectal cancer
- Keywords
- p53, TP53 mutation, tumor suppressor, mutation spectrum, transitions and transversions, colorectal cancer, lung cancer, esophageal cancer, breast cancer, liver cancer, brain tumors, leukemia, lymphoma, aflatoxin B1, hepatitis B virus, carcinogenesis
- MeSH terms
- Amino Acid Sequence, Animals, Haplorhini, Base Sequence, Chickens, DNA Mutational Analysis, Humans, Molecular Sequence Data, Mutation, Neoplasms, Sequence Homology, Nucleic Acid, Trout, Xenopus, Genes, p53, Mice, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
